ReissmannK.R.. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood1950; 5: 372–80.
2.
RadtkeH.W., ClausnerA., ErbesP.M.Serum erythropoietin concentration in chronic renal failure: relationship to the degree of anemia and excretory. renal function. Blood1979; 54: 877–84.
3.
Mq GonigleR.J.S., WallinJ.D., ShadduckR.K.Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int1984; 35: 437–44.
4.
LinF.K., SuggsS., LinC.H.Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sei USA1985; 82: 7580–4.
5.
EschbachJ.W.. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int1989; 35: 134–48.
6.
DordalM.S., WangF.F., GoldwasserE.. The role of carbohydrate in erythropoietin action. Endocrinology1985; 116: 2293–9.
7.
JacobsK., ShoemakerC., Ru-densdorfR.Isolation and characterization of genomic and c DNA clones of human erythropoietin. Nature1985; 313: 806–9.
8.
RecnyM.A., ScobleH.A., KimY.. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem1987; 262: 17156–63.
9.
LacombeC., Da SilvaJ.L., Bru-nevalP.Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest1988; 81: 620–3.
10.
KouryS.T., BondurantM.C., KouryM.J.. Localization of erythroprotein synthesizing cells in murine kidneys by in situ hybridization. Blood1988; 71: 524–7.
11.
FisherJ.W.. Pharmacological modulation of erythropoietin production. Ann Rev Pharmacol Toxicol1988; 28: 101–2.
12.
GoldwasserE.. Erythropoietin and the differentiation of red blood cells. Fed Proc1975; 34: 2285–92.
13.
WagemakerG., Ober-Kielten-burgV.E., BrouwerA., Peters-SloughM.F.. Some characteristics of in vitro erythroid colony and burst-forming units. In: Exp Hematology Today, BaumS.J., LedeneyG.D. eds. 1977; 103.
14.
IscoveN.N.. Erythropoietin independent regulation of early erythropoiesis. Exp Hematol (abs) 1977; 6.
15.
SawadaK., KrantzS.B., KansJ.S.Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest1987; 80: 357–66.
16.
LamperiS., CarozziS., IcardiA., NasiniM.G., TraversoG.B.. Cause dell'anemia nell'uremico e nuove prospettive terapeutiche. In: Attualità Nefrologiche e Dialitiche.Wichtig Editore1987; 193–200.
17.
IcardiA., TraversoG.B., PaolettiE., CappelliG., MolinelliG.. CAPD ed eritropoietina a basse dosi nel trattamento dell'anemia uremica. Atti del XXX Congreesso Nazionale Soc.Italiana di Nefrologia, Venezia1989 (in stampa).
18.
TraversoG.B., PaolettiE., SarchiC., IcardiA.. Red celi membrane during erythropoietin therapy in hemodialysis (HD) and in hemodiafiltration (HDF). Abstr XXVI ESAO Congress, Bruxelles 1989; 585.
19.
HughesR.T., CotesP.M., OliverD.O.Correction of the anaemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on haemodialysis and CAPD. Contr Nephrol1989; 76: 122–30.
EschbachJ.W., KellyM.R., HaleyN.R.Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med1989; 321: 158–63.
22.
IcardiA., PaolettiE., TraversoG.B., CappelliG., MolinelliG.. Terapia con eritropoietina ricombinante umana (r-HuE-PO) nell'anemia uremica in CAPD: via sottocutanea vs via intraperitoneale. In: Dialisi Peritoneale.BuoncristianiU. ed. Atti del V Convegno Nazionale, Perugia1989; 305–9.
23.
IcardiA., PaolettiE., MolinelliG.. Efficacy of recombinant erythropoietin after s.c. and i.p. administration to patients on continuous ambulatory peritoneal dialysis (CAPD). In: Advances in Continuous Ambulatory Peritonea] Dialysis, Xth Annual CAPD Conference, Dallas 1990 (in stampa).
24.
IcardiA., TraversoG.B., CappelliG., PaolettiE., MolinelliG.. Trattamento a lungo termine con eritropoietina ricombinante umana nei pazienti in emodialisi periodica. In: L'e-modiafiltrazione ed i trattamenti ad alti flussi.Wichtig Editore1989; 633–79.
25.
CasatiS., PasseriniP., CampiseM.R.Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J1987; 295: 1017–20.
26.
SchaeferR.M., LeschkeM., StraverB.E., HeidlandA.. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol1988; 8: 449–53.
27.
HenryD.H.. Treatment of anemia in patients with AIDS. Symp Abstr Ann Am Soc Hematol, (abstr.) 1988; 3.
28.
Nonnast-DanielB., CreutzigA., KuhnK.Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. Contr Nephrol1988; 66: 185–94.
29.
GranollerasC., DeschoottG., EisenbachG.Effect of recombinant human erythropoietin (EP) on haemofiltration (HF) and haemodiafiltration (HDF). Abstract EDTA-ERA, Madrid 1988; 206.
30.
MolinelliG., IcardiA., PaolettiE., TraversoG.B., CappelliG.. Long-term study of erythropoietin effects in chronic hemodialysis patients. XXVI ESAO Congress, Bruxelles 1989, Int J Artif Organs (in stampa).
31.
SteinhauerR.B., Lubrich-Bir-knerI., DreylingK.W., SchollmeyerP.. Human recombinant erythropoietin (r-hEPO) increases peritoneal ultrafiltration in CAPD patiens. Abstract EDTA Goteborg1989; 212.
32.
GretzN., LasserreJ.J., MeisingerE.Does erythropoietin promote a loss of renal function?Abstract EDTA-ERA, Madrid1988; 207.
33.
IcardiA., Di MaioG., TraversoG.B., LamperiD., PaolettiE., MolinelliG.. Effetti della eritropoietina ricombinante umana (r-HuEPO) nel trattamento dell'anemia uremica in pazienti in fase predialitica ed in emodialisi. Abstr 4a Riunione Congiunta Soc. de Nephrologie, Soc. Espanola de Nefrologia, Soc. Italiana di Nefrologia, Torino 1989; 112.